Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 123 participants.

Also called NCT04976283

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 123 participants (planned count) (from the registry)
Sponsor
  • Getz Pharma Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04976283
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04976283. Randomized; no masking; primary purpose treatment. Start 2021-09-15 (actual); primary completion 2023-05-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
Condition
Diabetes Mellitus, Type 2
Condition
NASH - Nonalcoholic Steatohepatitis
Condition
NAFLD
Intervention (Drug)
Pioglitazone
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Pioglitazone + Empagliflozin
Lead sponsor
Getz Pharma (class: industry)

Record details

Record id
cardio:ct-nct04976283
Content hash
bff838853283708e35e94f4d8aecff19c85bfe4775bce034b2a37d12d3d75451